Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA7 | P43166 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428498 | 0.84 | TSHR (0.56) | CA2CA12CA1CA7CA9 | |
| SCHEMBL29131163 | 0.82 | CA1 (0.49) | CA2CA12CA1CA7CA9 | |
| SCHEMBL95253 | 0.80 | CA2 (0.50) | CA2CA12CA1CA7CA9 | |
| SCHEMBL11750979 | 0.77 | CA12 (0.56) | CA2CA12CA1CA7CA9 | |
| SCHEMBL4423792 | 0.76 | MIF (0.42) | CA2CA12CA1CA7CA9 | |
| SCHEMBL9626909 | 0.73 | TSHR (0.70) | CA2CA12CA1CA7CA9 | |
| SCHEMBL8067640 | 0.71 | CA2 (0.52) | CA2CA12CA1CA7CA9 | |
| Isopropyl 3-(4-Hydroxyphenyl)Acrylate SCHEMBL4966894 | 0.70 | CA12 (1.00) | CA2CA12CA1CA7CA9 | |
| SCHEMBL8737269 | 0.70 | FNTA (0.52) | CA2CA12CA1CA7CA9 | |
| Isopropyl 3-(4-Hydroxyphenyl)Acrylate SCHEMBL4966886 | 0.70 | CA12 (1.00) | CA2CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | claimed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | claimed |
| EP-1572678-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1549622-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | Elian Pharmaceuticals Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| WO-2004033436-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | claimed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-1572678-A4 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARM INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004056319-A2 | SUBSTITUTED N-PHENYL SULFONAMIDE BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004033436-A1 | SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | CA2 715/4885CA12 3354/4885CA1 1606/4885 |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, HRH2 | CA2 2315/4885CA12 4360/4885CA1 2900/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | CA2 384/4885CA12 2479/4885CA1 1006/4885 |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | BDKRB1, BDKRB2, HRH2 | CA2 1053/4885CA12 2983/4885CA1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.